Abstract
Postmenopausal hyperhidrosis (PMH) is an important differential diagnosis to vasomotor symptoms (VMS) in menopause. The objective is to describe the differences in clinical presentation and treatment of the two conditions.
Highlights
Underlying PhysiologyPostmenopausal hyperhidrosis (PMH) is an important and overlooked differential diagnosis of vasomotor symptoms (VMS) during menopause
Patients suffering from PMH represent a unique cohort of patients with primary hyperhidrosis and should not be treated in the same way as those displaying VMS during menopause
This review explains the differences in clinical presentation and treatments and suggests botulinum toxin type B in the treatment of vasomotor symptoms due to anti-oestrogen therapy
Summary
• Postmenopausal hyperhidrosis (PMH) is primary and hereditary, where oestrogen replacement has no effect. • Vasomotor symptoms in menopause are due to reduced levels of oestrogen and can be treated with oestrogen replacement. • Botulinum toxin type B (Btx B) has the best effect and least side effects when treating PMH. • Vasomotor symptoms secondary to anti-oestrogen could be treated with Btx B to eliminate bothersome sweating.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
